[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corticobasal-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corticobasal-degeneration":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,45,64,106,147,175,205,231,277,304,353],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636721","a-wearable-sensor-platform-for-remote-monitoring-of-individuals-on-the-frontotemporal-dementia-spectrum-100636721",false,"NCT07569367","A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum","ReMoTe","Inclusion Criteria:\n\n* Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.\n* Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* Individuals who have a history of frequent falls defined as more than 5 falls per month.","ALL","40 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes. Researchers at BioSensics, Johns Hopkins University School of Medicine, and Massachusetts General Hospital will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 60 patients with FTLD syndromes for 24 months with study visits every 6 months.",[24,25,26,27],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Corticobasal Degeneration","Corticobasal Syndrome (CBS)",[29,30,31],"digital health","wearable sensors","frontotemporal lobar degeneration","NOT_YET_RECRUITING","2026-05-05",{"date":35,"type":36},"2026-05-08","ACTUAL",{"date":38,"type":20},"2026-08-01",{"date":40,"type":20},"2030-12-15",{"name":42,"class":43},"BioSensics","INDUSTRY",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100618613","digital-measurements-of-motor-and-voice-functions-in-ftd-100618613","NCT07333898","Digital Measurements of Motor and Voice Functions in FTD",{"count":51,"type":20},20,"The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes.\n\nResearchers at BioSensics and Johns Hopkins School of Medicine will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 20 patients with FTLD syndromes for 12 months with study visits every 3 months.",[24,25,54,55,26],"Corticobasal Syndrome","Corticobasal Syndrome(CBS)",[29,30,31],"2026-04-23",{"date":59,"type":36},"2026-04-28",{"date":38,"type":20},{"date":62,"type":20},"2028-12-31",{"name":42,"class":43},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":93,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":44},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.",true,"20 Years","100 Years",{"count":75,"type":20},2950,"INTERVENTIONAL",[78],"NA","The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[81,82,83,84,85,86,87,88,89,26,90,91,92],"Dementia","Alzheimer Disease","Parkinson Disease","Lewy Body Disease","Parkinson-Dementia Syndrome","Frontotemporal Degeneration","Semantic Dementia","Progressive Nonfluent Aphasia","Progressive Supranuclear Palsy","Multiple System Atrophy","Mild Cognitive Impairment","ALS (Amyotrophic Lateral Sclerosis)",[94],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test","RECRUITING","2026-04-01",{"date":98,"type":36},"2026-04-06",{"date":100,"type":36},"2017-05-15",{"date":102,"type":20},"2036-12",{"name":104,"class":105},"Skane University Hospital","OTHER",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":71,"sex":16,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":131,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.","35 Years",{"count":114,"type":20},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[117,118,54,55,119,26,120,27,121,122,123,90,124,125,126,127,128,89,129,130],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Degeneration Syndrome","Corticobasal Degeneration (CBD)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[132,89,90,133,134,117,121,135,136],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":139,"type":36},"2026-01-14",{"date":141,"type":36},"2024-10-08",{"date":143,"type":20},"2030-12-31",{"name":145,"class":105},"Massachusetts General Hospital",1,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":76,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":146},"100489489","scrambler-therapy-for-corticobasal-syndrome-associated-pain-100489489","NCT05653778","Scrambler Therapy for Corticobasal Syndrome-Associated Pain","ST-CBS","Inclusion Criteria:\n\n* men and women, ≥50 years of age or older with CBS with an average daily pain rating of \\> 4 out of 10, using the following question from the Brief Pain Inventory: \"Please rate your pain by circling the one number that best describes your (abdominal) pain\u002Fdiscomfort on average over the past week. (Scale 0-10; 0= No pain, 10= Pain as bad as you can imagine)\n* English speakers or English proficiency\n* They must have a life expectancy \\> 90 days per their treating neurologist.\n* The patient must be able to understand the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women, nursing women, women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device, surgical sterilization, subcutaneous implants, abstinence, etc.). Other exclusions include the following:\n* Use of an investigational agent for pain control concurrently or within the past 30 days,\n* History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation;\n* Patients with implantable drug delivery systems, e.g. Medtronic Synchromed, baclofen pumps.\n* Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, cochlear implants, aneurysm clips, vena cava clips and skull plates. (Metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed).\n* Medical exclusions include: patients with a history of myocardial infarction or ischemic heart disease within the past six months; patients with history of epilepsy, brain damage, or symptomatic brain metastases; skin conditions such as open sores that would prevent proper application of the electrodes; or other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study.","50 Years","89 Years",{"count":157,"type":20},25,[78],"The goal of this pilot trial is to test whether scrambler therapy (ST) is an effective treatment for neuropathic pain in patients with corticobasal syndrome (CBS).\n\nThe main question it aims to answer is:\n\nWill ST reduce pain scores by at least 33% at one month in this pilot trial, justifying further multi-center trials?\n\nParticipants will:\n\n* be randomly assigned treatment from either transcutaneous electrical nerve stimulation (TENS) or ST for pain initially (eventually all patients will receive ST).\n* have superficial electrocardiogram (ECG) electrodes placed on the dermatomes involved with pain\n* obtain treatment lasting 30-40 minutes or until pain relief is obtained\n\nResearchers will compare patient's response to pain relief with TENS and ST to determine if ST is an effective treatment for central neuropathic pain.",[26,54,161],"Pain, Neuropathic",[26,163,164,165,166],"scrambler therapy","Corticobasal syndrome","neuropathic pain","neuropathy",{"date":168,"type":36},"2026-01-13",{"date":170,"type":36},"2024-04-05",{"date":172,"type":20},"2027-02",{"name":174,"class":105},"Johns Hopkins University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":71,"sex":16,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":146},"100593008","imaging-studies-in-corticobasal-syndrome-100593008","NCT07000851","Imaging Studies in Corticobasal Syndrome","Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome","I-CAN","Inclusion Criteria:\n\n* Age 18 years or older\n* Meet possible or probable CBS criteria\n\nExclusion Criteria:\n\n* Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)\n* Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome\n* Subjects will be excluded if they have a mutation in the progranulin gene\n* Subjects will excluded if they have received anti-Aβ therapy\n* Women who are pregnant will be excluded\n* Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)\n* Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid\u002Fglucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning","18 Years",{"count":185,"type":20},80,"The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.",[188,54,55,26,120,27],"Cortico Basal Degeneration",[190,191,192,193,194,195],"neurodegeneration","neurodegenerative disease","cbs","cbd","corticobasal syndrome","corticobasal degeneration","2025-07-03",{"date":198,"type":36},"2025-07-07",{"date":200,"type":36},"2025-06-25",{"date":202,"type":20},"2031-03-30",{"name":204,"class":105},"Jennifer Whitwell",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":71,"sex":16,"minAge":183,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":146},"100285367","gait-analysis-in-neurological-disease-100285367","NCT02994719","Gait Analysis in Neurological Disease","Gait Pattern Analysis in Neurological Disease","Inclusion Criteria:\n\n* Age 18-85 (for both healthy and affected subjects).\n* Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).\n* Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).\n* These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).\n* Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).\n* Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).\n\nExclusion Criteria:\n\n* Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).\n* Currently being treated for major medical illness requiring recent hospitalization (\\\u003C14 days) (for both healthy and affected subjects).\n* Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).\n* Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).\n* Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \\\u003C 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).","85 Years",{"count":214,"type":20},120,"The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.",[217,218,219,89,90,26,220,221],"Parkinson's Disease","Parkinsonian Disorders","Atypical Parkinson Disease","Gait, Frontal","Huntington Disease","2025-06-05",{"date":224,"type":36},"2025-06-08",{"date":226,"type":36},"2016-03-01",{"date":228,"type":20},"2026-06-20",{"name":230,"class":105},"Beth Israel Deaconess Medical Center",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":237,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":240,"conditions":241,"keywords":263,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":146},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":239,"type":20},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[242,243,82,244,245,246,26,81,247,221,84,248,90,83,249,89,250,251,252,253,254,255,256,257,258,259,260,261,262],"ALS","Amyotrophic Lateral Sclerosis","Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Frontotemporal Dementia","Multiple Sclerosis","Parkinson's Disease and Parkinsonism","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[242,243,82,246,26,81,247,221,84,248,90,83,264,89,250,251,265,266,255,267,256,257,258,259,260,261,262],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":270,"type":36},"2025-03-03",{"date":272,"type":36},"2022-11-10",{"date":274,"type":20},"2045-11-10",{"name":276,"class":105},"New York Stem Cell Foundation Research Institute",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":76,"phases":286,"briefSummary":287,"conditions":288,"keywords":293,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":146},"100529528","the-use-of-the-cue1cue1-in-people-with-parkinsons-disease-and-related-disorders-100529528","NCT06174948","The Use of the CUE1\u002FCUE1+ in People With Parkinson's Disease and Related Disorders","The Use of the CUE1\u002FCUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adults over 18 years old\n* Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)\n* willing to participate and written consent provided after read the participant information sheet.\n\nExclusion Criteria:\n\nIndividuals with:\n\n* other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait\n* metabolic or autoimmune disorders affecting movement, balance and gait\n* acute orthopaedic disorders influencing balance control and gait\n* audiovestibular disorders including severe hearing loss\n* visual disturbances, poor eyesight\n* not able to provide written consent form to participate\n* clinical diagnosis of cognitive impairment including dementia or Alzheimer's.\n* Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)\n\nTechnical contraindications related to CUE1 device:\n\n* implanted metallic or electronic devices usage\n* hypersensitivity to vibrotactile stimulation\n* skin conditions and\u002For open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.",{"count":285,"type":20},70,[78],"People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioural disturbances, autonomic dysfunction, cognitive impairment, sleep dysfunction and olfactory loss) features. Currently, it is challenging to alleviate these symptoms with first-line treatment, the medications such as levodopa. The CUE1 is a non-invasive device, which is approved for sale in the UK market as a Class I low risk device. It is worn on the sternum or other part of the body such as the forearm and attaches to the skin via an adhesive patch which has been dermatologically tested and approved.\n\nThe CUE1 delivers pulsing cueing and vibrotactile stimulation to help improve symptoms in people with PD and it has shown to be effective in doing so in previous small case studies. This 9-week feasibility study aims to investigate the feasibility, safety, tolerability and effect of using the CUE1 as an intervention to improve motor and non-motor symptoms in people with PD and related movement disorders. People with clinical diagnosis of idiopathic PD and related disorders including those with progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, orthostatic tremor and vascular Parkinsonism as well as atypical dystonias and tremor disorders aged over 18 years old who have the capacity to provide a written consent form to take part in the study, will receive as intervention to wear the CUE1 device at home, on daily basis while carrying out their activities of daily living. Participants will also have to attend face-to-face appointments of approximately half a day, to discuss how they are getting on with using the CUE1 and complete questionnaires on their symptoms, walking, balance, and movement tests as well as a participant's clinical diary.",[249,89,289,290,90,26,291,292],"Different Types of Tremor Including Essential Tremor","Dystonia","Vascular Parkinsonism","Orthostatic Tremor",[294],"CUE1, Parkinson's disease, movement disorders","2024-11-18",{"date":297,"type":36},"2024-11-21",{"date":299,"type":36},"2024-03-25",{"date":301,"type":20},"2025-03-31",{"name":303,"class":105},"Queen Mary University of London",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":315,"conditions":316,"keywords":328,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":146},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":314,"type":20},600,"MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[317,83,318,84,90,319,82,26,320,321,322,243,323,324,325,81,326,327],"Neurodegenerative Diseases","Synucleinopathies","Tauopathies","Supranuclear Palsy, Progressive","Atypical Parkinsonism","TDP-43 Proteinopathies","Frontotemporal Lobar Degeneration","Movement Disorders","Cognitive Impairment","Iron Overload","Neurodegeneration With Brain Iron Accumulation (NBIA)",[317,329,330,331,332,333,334,335,336,337,338,339,340,341,342],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":345,"type":36},"2024-09-19",{"date":347,"type":20},"2024-09-09",{"date":349,"type":20},"2034-09-09",{"name":351,"class":352},"Casa di Cura San Raffaele Cassino","NETWORK",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":360,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":363,"conditions":364,"keywords":369,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":146},"100224095","modifiable-variables-in-parkinsonism-mvp-100224095","NCT02194816","Modifiable Variables in Parkinsonism (MVP)","Modifiable Variables in Parkinsonism (MVP) [Formerly CAM Care in PD]","Inclusion Criteria:\n\n* Parkinson's disease (PD)\n* Parkinsonism\n* Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)\n* Must have online access, an email address, basic computer literacy\n* Must be willing to complete online surveys every 6 months for 5 years\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite English\n* Inability or unwillingness to complete surveys every six (6) months (\\~90 min)","19 Years",{"count":362,"type":20},2000,"We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.",[217,264,122,89,365,26,366,367,368],"Shy-Drager Syndrome","Dementia With Lewy Bodies","Pick Disease","Olivopontocerebellar Atrophies",[217,370,371,372],"PD","Complementary and Alternative","CAM","2022-03-10",{"date":375,"type":36},"2022-03-25",{"date":377,"type":4},"2012-09",{"date":379,"type":20},"2030-12",{"name":381,"class":105},"Bastyr University"]